BSBE

Beijing Strong Biotechnologies, Inc. (BSBE) is one of the leading suppliers of clinical in vitro diagnostic products and services in China. Established in 2001, it is a national high-tech enterprise with core businesses in the research, production, and sales of in vitro diagnostic products. The company has an in vitro diagnostic product series that develops in sync with international standards. Located in Beijing, its registered capital is RMB 587,427,728. It was successfully listed on the Growth Enterprise Market in 2014, with the stock code 300406. As one of the leading enterprises in China’s in vitro diagnostics industry, the company is committed to building the best in vitro diagnostic testing platform. Currently, it has biochemical detection systems, coagulation detection systems, luminescence detection systems, blood type detection systems, POCT detection systems, pathological detection systems, and liquid biopsy CTC. In 2020, Sinopharm invested in BSBE, jointly planning the field of medical device in vitro diagnostics. Years of stable development and comprehensive accumulation have formed a marketing and service network across China. The company has consistently focused on the research and development of in vitro diagnostic product systems, possessing a top-notch R&D team. It has established biochemical R&D platforms including chemical methods, enzymatic methods (including cyclic enzymatic methods), conventional immunoturbidimetric methods, latex-enhanced immunoturbidimetric methods, cloned enzyme donor immunoassay technology (CEDIA), and enzyme-multiplied immunoassay technique (EMIT). Additionally, it has a high-level full-liquid coagulation R&D technical team. In 2018, blood type detection products based on the microcolumn gel method were launched, marking BSBE's official entry into the blood matching detection field. In the field of oncopathology, the company's products cover reagents and fully automated immunohistochemical pathology staining systems needed for routine tumor pathology diagnosis and differential diagnosis in hospital pathology departments. It has also built monoclonal antibody preparation technology, fully automated pathology detection systems, and molecular pathology test reagent and instrument research platforms such as fluorescence in situ hybridization, actively expanding into the molecular pathology diagnosis field and exploring diversified services and technological approaches. The company’s R&D center is a National Enterprise Technology Center and the "Beijing Engineering Laboratory for Biochemical and Immune Diagnostic Reagents." Moreover, the company is a co-developer and manufacturer of the national CysC standard material and undertakes multiple projects from the Ministry of Science and Technology and the National Development and Reform Commission. In 2021, the project "Establishment and Application of a Cardiovascular Injury Prevention System in Military Operational Environments," completed in collaboration with the Chinese PLA General Hospital, won the second prize of the National Science and Technology Progress Award.